Does the media refer more to GYRE or RARE?

In the previous week, Ultragenyx Pharmaceutical had 5 more articles in the media than Gyre Therapeutics. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 3 mentions for Gyre Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.78 beat Gyre Therapeutics' score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ultragenyx Pharmaceutical 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GYRE or ATAI?

In the previous week, Gyre Therapeutics had 1 more articles in the media than Atai Beckley. MarketBeat recorded 3 mentions for Gyre Therapeutics and 2 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.44 beat Gyre Therapeutics' score of 0.00 indicating that Atai Beckley is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atai Beckley 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer GYRE or KOD?

In the previous week, Kodiak Sciences had 4 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for Kodiak Sciences and 3 mentions for Gyre Therapeutics. Kodiak Sciences' average media sentiment score of 1.24 beat Gyre Therapeutics' score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GYRE or TARS?

In the previous week, Tarsus Pharmaceuticals had 5 more articles in the media than Gyre Therapeutics. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 3 mentions for Gyre Therapeutics. Tarsus Pharmaceuticals' average media sentiment score of 0.85 beat Gyre Therapeutics' score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BEAM or GYRE?

In the previous week, Beam Therapeutics had 8 more articles in the media than Gyre Therapeutics. MarketBeat recorded 11 mentions for Beam Therapeutics and 3 mentions for Gyre Therapeutics. Beam Therapeutics' average media sentiment score of 0.93 beat Gyre Therapeutics' score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Gyre Therapeutics (GYRE) Competitors

$6.11 +0.36 (+6.26%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$6.08 -0.03 (-0.41%)

As of 05:31 AM Eastern

Compare

GYRE vs. RARE, ATAI, KOD, TARS, and BEAM

Should you buy Gyre Therapeutics stock or one of its competitors? MarketBeat compares Gyre Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gyre Therapeutics include Ultragenyx Pharmaceutical (RARE), Atai Beckley (ATAI), Kodiak Sciences (KOD), Tarsus Pharmaceuticals (TARS), and Beam Therapeutics (BEAM).

How does Gyre Therapeutics compare to Ultragenyx Pharmaceutical?

Gyre Therapeutics (NASDAQ:GYRE) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Gyre Therapeutics has a net margin of -5.44% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Gyre Therapeutics' return on equity of 3.13% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

Gyre Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 178.23%. Ultragenyx Pharmaceutical has a consensus price target of $58.41, indicating a potential upside of 133.46%. Given Gyre Therapeutics' higher possible upside, research analysts clearly believe Gyre Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Gyre Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	5.84	$5.03M	-$0.09	N/A
Ultragenyx Pharmaceutical	$673M	3.66	-$575M	-$6.11	N/A

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Gyre Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

In the previous week, Ultragenyx Pharmaceutical had 5 more articles in the media than Gyre Therapeutics. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 3 mentions for Gyre Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.78 beat Gyre Therapeutics' score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Gyre Therapeutics beats Ultragenyx Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Gyre Therapeutics compare to Atai Beckley?

Gyre Therapeutics (NASDAQ:GYRE) and Atai Beckley (NASDAQ:ATAI) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

In the previous week, Gyre Therapeutics had 1 more articles in the media than Atai Beckley. MarketBeat recorded 3 mentions for Gyre Therapeutics and 2 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.44 beat Gyre Therapeutics' score of 0.00 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atai Beckley	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gyre Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 178.23%. Atai Beckley has a consensus target price of $11.06, indicating a potential upside of 53.99%. Given Gyre Therapeutics' higher possible upside, research analysts clearly believe Gyre Therapeutics is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Atai Beckley	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.27

Gyre Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 19.8% of Atai Beckley shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Gyre Therapeutics has higher revenue and earnings than Atai Beckley. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	5.84	$5.03M	-$0.09	N/A
Atai Beckley	$4.09M	646.32	-$660.05M	-$2.23	N/A

Gyre Therapeutics has a net margin of -5.44% compared to Atai Beckley's net margin of -19,019.44%. Gyre Therapeutics' return on equity of 3.13% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Summary

Gyre Therapeutics beats Atai Beckley on 10 of the 17 factors compared between the two stocks.

How does Gyre Therapeutics compare to Kodiak Sciences?

Gyre Therapeutics (NASDAQ:GYRE) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Gyre Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 178.23%. Kodiak Sciences has a consensus price target of $48.14, suggesting a potential upside of 20.87%. Given Gyre Therapeutics' higher possible upside, equities analysts clearly believe Gyre Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Gyre Therapeutics has higher revenue and earnings than Kodiak Sciences. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	5.84	$5.03M	-$0.09	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Kodiak Sciences has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Kodiak Sciences	N/A	-253.85%	-81.48%

Gyre Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Kodiak Sciences had 4 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for Kodiak Sciences and 3 mentions for Gyre Therapeutics. Kodiak Sciences' average media sentiment score of 1.24 beat Gyre Therapeutics' score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kodiak Sciences	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kodiak Sciences beats Gyre Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Gyre Therapeutics compare to Tarsus Pharmaceuticals?

Gyre Therapeutics (NASDAQ:GYRE) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Gyre Therapeutics has a net margin of -5.44% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Gyre Therapeutics' return on equity of 3.13% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Gyre Therapeutics has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	5.84	$5.03M	-$0.09	N/A
Tarsus Pharmaceuticals	$451.36M	5.84	-$66.42M	-$1.14	N/A

Gyre Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 178.23%. Tarsus Pharmaceuticals has a consensus price target of $90.17, suggesting a potential upside of 47.04%. Given Gyre Therapeutics' higher possible upside, research analysts clearly believe Gyre Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Tarsus Pharmaceuticals had 5 more articles in the media than Gyre Therapeutics. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 3 mentions for Gyre Therapeutics. Tarsus Pharmaceuticals' average media sentiment score of 0.85 beat Gyre Therapeutics' score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Gyre Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Summary

Tarsus Pharmaceuticals beats Gyre Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Gyre Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Gyre Therapeutics (NASDAQ:GYRE) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Beam Therapeutics currently has a consensus target price of $46.85, indicating a potential upside of 80.80%. Gyre Therapeutics has a consensus target price of $17.00, indicating a potential upside of 178.23%. Given Gyre Therapeutics' higher probable upside, analysts clearly believe Gyre Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Beam Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

Gyre Therapeutics has lower revenue, but higher earnings than Beam Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	19.08	-$79.99M	-$0.68	N/A
Gyre Therapeutics	$116.59M	5.84	$5.03M	-$0.09	N/A

Gyre Therapeutics has a net margin of -5.44% compared to Beam Therapeutics' net margin of -39.66%. Gyre Therapeutics' return on equity of 3.13% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Gyre Therapeutics	-5.44%	3.13%	2.67%

In the previous week, Beam Therapeutics had 8 more articles in the media than Gyre Therapeutics. MarketBeat recorded 11 mentions for Beam Therapeutics and 3 mentions for Gyre Therapeutics. Beam Therapeutics' average media sentiment score of 0.93 beat Gyre Therapeutics' score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Beam Therapeutics beats Gyre Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Gyre Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GYRE vs. The Competition

Export

Metric	Gyre Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$641.06M	$11.61B	$6.86B	$12.43B
Dividend Yield	N/A	2.73%	2.60%	10.03%
P/E Ratio	-67.88	793.98	280.72	24.99
Price / Sales	5.84	942.39	644.56	112.42
Price / Cash	25.88	14.82	28.64	34.82
Price / Book	4.13	10.45	11.07	6.21
Net Income	$5.03M	$2.80B	$3.48B	$347.49M
7 Day Performance	2.00%	0.77%	0.83%	1.28%
1 Month Performance	-16.76%	-3.79%	-4.14%	-3.62%
1 Year Performance	-12.96%	154.77%	61.50%	18.37%

Gyre Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GYRE Gyre Therapeutics	1.6857 of 5 stars	$6.11 +6.3%	$17.00 +178.2%	-8.1%	$641.06M	$116.59M	N/A	40	News Coverage Positive News Upcoming Earnings
RARE Ultragenyx Pharmaceutical	3.6115 of 5 stars	$25.98 -3.4%	$58.41 +124.8%	-12.0%	$2.65B	$673M	N/A	1,371
ATAI Atai Beckley	2.7315 of 5 stars	$7.18 +0.1%	$11.06 +54.0%	+72.2%	$2.64B	$4.09M	N/A	80
KOD Kodiak Sciences	2.6437 of 5 stars	$40.29 -3.9%	$42.14 +4.6%	+498.9%	$2.62B	N/A	N/A	90	Positive News Analyst Forecast
TARS Tarsus Pharmaceuticals	3.8216 of 5 stars	$58.95 -1.9%	$90.50 +53.5%	+50.3%	$2.59B	$451.36M	N/A	50	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GYRE) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gyre Therapeutics (GYRE) Competitors

GYRE vs. RARE, ATAI, KOD, TARS, and BEAM

How does Gyre Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does Gyre Therapeutics compare to Atai Beckley?

Summary

How does Gyre Therapeutics compare to Kodiak Sciences?

Summary

How does Gyre Therapeutics compare to Tarsus Pharmaceuticals?

Summary

How does Gyre Therapeutics compare to Beam Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gyre Therapeutics (GYRE) Competitors

GYRE vs. RARE, ATAI, KOD, TARS, and BEAM

How does Gyre Therapeutics compare to Ultragenyx Pharmaceutical?

Is GYRE or RARE more profitable?

Do analysts recommend GYRE or RARE?

Which has stronger earnings & valuation, GYRE or RARE?

Do institutionals & insiders hold more shares of GYRE or RARE?

Which has more volatility and risk, GYRE or RARE?

Does the media refer more to GYRE or RARE?

Summary

How does Gyre Therapeutics compare to Atai Beckley?

Does the media favor GYRE or ATAI?

Do analysts prefer GYRE or ATAI?

Which has more risk and volatility, GYRE or ATAI?

Do institutionals & insiders believe in GYRE or ATAI?

Which has better earnings & valuation, GYRE or ATAI?

Is GYRE or ATAI more profitable?

Summary

How does Gyre Therapeutics compare to Kodiak Sciences?

Do analysts rate GYRE or KOD?

Which has preferable earnings & valuation, GYRE or KOD?

Is GYRE or KOD more profitable?

Which has more risk and volatility, GYRE or KOD?

Do insiders & institutionals hold more shares of GYRE or KOD?

Does the media prefer GYRE or KOD?

Summary

How does Gyre Therapeutics compare to Tarsus Pharmaceuticals?

Is GYRE or TARS more profitable?

Which has stronger valuation and earnings, GYRE or TARS?

Do analysts rate GYRE or TARS?

Do insiders & institutionals believe in GYRE or TARS?

Does the media favor GYRE or TARS?

Which has more risk and volatility, GYRE or TARS?

Summary

How does Gyre Therapeutics compare to Beam Therapeutics?

Do analysts recommend BEAM or GYRE?

Which has more volatility and risk, BEAM or GYRE?

Which has stronger valuation & earnings, BEAM or GYRE?

Is BEAM or GYRE more profitable?

Does the media refer more to BEAM or GYRE?

Do institutionals and insiders have more ownership in BEAM or GYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools